RxDoctor Payments Data

Mohammad Ismail, MD

Neurology · Carlisle, PANPI 1821052812

Payments from drug & device makers

$105,786in general payments, 2019–2025

Across 726 payments — averaging $145.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$60K
  • Acadia Pharmaceuticals Inc$33K
  • AbbVie$1K
  • Bristol Myers Squibb$844
  • Biogen$794
  • Microvention, Inc.$704
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$240%
  • Travel & lodging$5644%
  • Food & beverage$12,25694%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Akebia Therapeutics Inc40$59,730
Acadia Pharmaceuticals Inc29$33,417
AbbVie(2 entities)93$1,435
Bristol Myers Squibb45$844
Biogen43$794
Microvention, Inc.2$704
Teva Pharmaceuticals USA, Inc.34$701
AstraZeneca(2 entities)25$625
EMD Serono, Inc.31$616
Novartis34$485
Amneal Pharmaceuticals LLC29$433
Lilly USA, LLC23$422
Eisai Inc.18$300
Neurocrine Biosciences, Inc.16$294
Jazz Pharmaceuticals Inc.11$291
Lundbeck LLC14$277
MDD US Operations, LLC14$247
Genentech USA, Inc.12$233
Argenx US, Inc.10$230
TG Therapeutics, Inc.9$221
Neurelis, Inc.12$211
Pfizer11$207
Sanofi10$182
Otsuka America Pharmaceutical, Inc.9$169
CSL Behring8$159
Biohaven Pharmaceutical Holding Company Ltd.8$150
Amgen8$149
Takeda Pharmaceuticals U.S.A., Inc.9$147
SK Life Science, Inc.8$137
Supernus Pharmaceuticals, Inc.9$134
Catalyst Pharmaceuticals, Inc.7$133
UCB, Inc.7$131
Harmony Biosciences LLC7$116
Axsome Therapeutics, Inc.5$113
Kyowa Kirin, Inc.6$112
Biohaven Pharmaceuticals, Inc.5$90
E.r. Squibb & Sons, L.L.C.5$88
Ipsen Biopharmaceuticals, Inc6$82
Adamas Pharmaceuticals, Inc.5$72
Upsher-smith Laboratories LLC4$70
Johnson & Johnson3$65
Tanabe Pharma America, Inc.4$64
Sumitomo Pharma America, Inc.4$64
Medtronic1$61
Scilex Pharmaceuticals Inc.3$58
Greenwich Biosciences, Inc.3$50
Avadel CNS Pharmaceuticals, LLC2$48
Avanir Pharmaceuticals, Inc.3$39
Mallinckrodt Enterprises LLC2$39
Assertio Therapeutics, Inc.3$37
Merz Pharmaceuticals, LLC2$37
Almatica Pharma LLC2$33
Mallinckrodt Hospital Products Inc.2$31
Averitas Pharma Inc.1$25
Acorda Therapeutics, Inc2$24
Avion Pharmaceuticals1$24
Novo Nordisk1$24
Vanda Pharmaceuticals Inc.1$21
Livanova USA, Inc.1$21
Idorsia Pharmaceuticals US Inc1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,786 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$314,933
Medicare patients
779
Services billed
15,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$363,589
Glatiramer Acetate14$68,475
BotoxOnabotulinumtoxina26$41,821
Nurtec OdtRimegepant Sulfate15$39,981
FycompaPerampanel16$39,517
MyrbetriqMirabegron38$18,657
RytaryCarbidopa/Levodopa18$14,872
Duloxetine Hcl479$12,117
Ajovy AutoinjectorFremanezumab-Vfrm12$9,704
Rasagiline Mesylate25$9,169
Memantine Hcl187$7,043
Gabapentin226$6,113
Levetiracetam147$4,536
Carbidopa-LevodopaCarbidopa/Levodopa152$3,983
Carbidopa-Levodopa ErCarbidopa/Levodopa41$3,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$294$363,58931 claims
AbbVieBotox$1,435$41,82126 claims
PfizerNurtec Odt$207$39,98115 claims
Eisai Inc.Fycompa$300$39,51716 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$433$17,72662 claims
Upsher-smith Laboratories LLCTopiramate$70$48952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Carlisle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →